German biotech TQ Therapeutics announced the acquisition of cell therapy company Juno Therapeutics GmbH, a German subsidiary of Bristol Myers Squibb’s Juno Therapeutics.
TQx aims to transform the traditional production of cell therapies towards a decentralized, scalable, fast and highly automated cost-efficient platform. The acquisition of Juno GmbH will increase TQx’s capabilities, expanding access to intellectual property and license agreements that will support the development of the company’s potentially transformative cell processing platform.
“This acquisition presents an incredible opportunity for us to continue development of our breakthrough ultra-short extracorporeal cell and gene therapy approach to create treatments of the future,” said Dr. Christian Eckert, CEO of TQx. “This strategic transaction reinforces our commitment to making cell and gene therapy broadly accessible to address the medical needs of many patients.”
The financial terms of the agreement were not disclosed.
Juno GmbH was a product of Juno Therapeutics’ purchase of Stage Cell Therapeutics in 2022. Juno acquired the 23-person biotech for an upfront payment of $59 million, creating a wholly-owned German subsidiary under the name Juno Therapeutics GmbH. Stage Cell/Juno GmbH offers next-gen cell isolation and expansion technology platforms, based on fully reversible reagents that enable the advanced isolation and expansion of T-cells during the manufacturing process.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!